Fractalkine/CX3CL1 in Neoplastic Processes

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Fractalkine (CX3CL1) is a chemokine crucial for lymphocyte function, including NK cells, T cells, and dendritic cells.
• CX3CL1 levels in tumors can predict patient prognosis, improving it in some cases but worsening it in others, like pancreatic cancer.

Purpose of the Study:

• To explore the 'hallmarks of cancer' associated with CX3CL1 and its receptor CX3CR1.
• To detail CX3CL1's role in cancer progression, including angiogenesis, apoptosis resistance, and metastasis.
• To examine CX3CL1's interactions within the tumor microenvironment and its potential in immunotherapy.

Main Methods:

• Review of signal transduction pathways involving CX3CR1 and EGFR.
• Analysis of CX3CL1's involvement in cancer hallmarks: angiogenesis, apoptosis resistance, migration, and invasion.
• Discussion of CX3CL1's interactions with tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), and microglia.

Main Results:

• CX3CL1 signaling, influenced by EGFR, affects cancer progression.
• CX3CL1 plays a role in perineural invasion, spinal, and bone metastasis for breast, pancreatic, and prostate cancers.
• CX3CL1 modulates immune cell populations within the tumor niche and is implicated in HCMV infection in GBM.

Conclusions:

• CX3CL1 is a significant factor in cancer biology, affecting tumor growth, metastasis, and immune cell interactions.
• Understanding CX3CL1's complex roles offers potential therapeutic strategies, particularly in immunotherapy.
• CX3CL1's involvement in metastasis and immune modulation warrants further investigation for targeted cancer treatments.